

Amendments to the Claims

This listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

- 1-24. (canceled)
25. (currently amended) An isolated oligonucleotide from about 10 to about 30 nucleobases in length comprising a sequence of at least 8 contiguous nucleobases of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 or an RNA sequence corresponding thereto, wherein the isolated oligonucleotide which is substantially at least about 95% homologous over its full length to SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 identical or complementary to at least a portion of SEQ ID NO: 21 or an the RNA sequence corresponding thereto.
26. (currently amended) The oligonucleotide of Claim 25 which is specifically hybridizable wherein the sequence is substantially identical or complementary to SEQ ID NO: 17, SEQ ID NO: 21, or an RNA sequence corresponding thereto.
27. (currently amended) The oligonucleotide of Claim 25 wherein the which sequence is substantially identical or complementary to SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 or an RNA sequence corresponding thereto.
28. (currently amended) The oligonucleotide of Claim 25 wherein the substantially identical or complementary sequence which is about 10-23 nucleobases in length.
29. (original) The oligonucleotide of Claim 25 which is an RNA oligonucleotide.
30. (original) The oligonucleotide of Claim 25 which comprises a non-naturally occurring nucleobase, sugar or internucleotide linkage.

31. (original) The oligonucleotide of Claim 30 which comprises a phosphorothioate internucleotide linkage.
32. (original) A composition comprising the oligonucleotide of Claim 25 and a pharmaceutically acceptable carrier, diluent or adjuvant.
- 33-42. (canceled)